Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Procore Technologies Insider Sale: A Strategic Move or Cause for Concern?

Robert Sasse by Robert Sasse
September 21, 2025
in Analysis, Insider Trading, Tech & Software
0
Procore Technologies Stock
0
SHARES
102
VIEWS
Share on FacebookShare on Twitter

A director at construction software firm Procore Technologies recently disposed of company stock worth over a million dollars. However, this transaction was executed under a pre-arranged trading plan, raising questions about its true significance for investors.

Strong Quarterly Performance

Before examining the insider activity, it’s important to note Procore’s robust fundamental performance. The company’s Q2 2025 results significantly surpassed Wall Street forecasts. It reported earnings per share of $0.35, handily beating the $0.24 consensus estimate. Revenue also showed healthy growth, climbing 13.9% year-over-year. In a further strategic development announced in August, Procore revealed a new partnership with Amazon Web Services aimed at accelerating AI solution development for the construction sector.

Pre-Planned Stock Disposal

Director Kevin J. O’Connor sold shares valued at approximately $1.1 million in mid-September. Crucially, this was not a discretionary trade but part of a 10b5-1 trading plan established back in November 2024. These regulatory-compliant plans allow corporate insiders to schedule future transactions in advance, thereby avoiding potential accusations of trading on non-public information. Following this sale, O’Connor retains a substantial ownership stake in the company.

Should investors sell immediately? Or is it worth buying Procore Technologies?

Mixed Analyst Sentiment

Market experts maintain a generally positive but cautious outlook on Procore’s equity. The majority of analysts continue to rate the stock as a “Buy” or “Hold,” with the average price target sitting at $83.06—well above current trading levels. However, DA Davidson recently initiated coverage with a more conservative “Neutral” rating and a $70 price target.

The upcoming quarterly report, due in late October, may provide greater clarity for shareholders. The key question remains whether this scheduled sale reflects a lack of confidence or simply represents prudent personal financial management by an insider.

Ad

Procore Technologies Stock: Buy or Sell?! New Procore Technologies Analysis from February 8 delivers the answer:

The latest Procore Technologies figures speak for themselves: Urgent action needed for Procore Technologies investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Procore Technologies: Buy or sell? Read more here...

Tags: Procore Technologies
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Ammo Stock
Analysis

Outdoor Holding Company’s Pivot Faces Crucial Quarterly Test

February 8, 2026
Berry Petroleum Stock
Analysis

California Resources Navigates Post-Merger Integration and Regulatory Landscape

February 8, 2026
KemPharm Stock
Analysis

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

February 8, 2026
Next Post
Carpenter Stock

Carpenter Technology: A Defense Sector Transformation Unfolds

BigBear.ai Stock

BigBear.ai Shares Soar Despite Troubling Financial Performance

Coinbase Stock

Coinbase's Strategic Expansion: Acquisitions and Innovation Drive Growth Ambitions

Recommended

Amazon Stock

Amazon’s AI Ambitions: Strategic Pivot or Costly Gamble?

5 months ago
BAE Systems Stock

BAE Systems Navigates Labor Challenges Amid Record Contract Backlog

5 months ago
Biotechnology Stock Bull Market

B of A Securities Upgrades Apple to Buy Expects Growth with AI and Vision Pro

2 years ago
BioNTech Stock

Can BioNTech Reinvent Itself Beyond the Pandemic?

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

SuRo Capital Sharpens Focus on AI Infrastructure Investments

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

DroneShield Shares Face Headwinds Despite Record Performance

Trending

Ammo Stock
Analysis

Outdoor Holding Company’s Pivot Faces Crucial Quarterly Test

by Jackson Burston
February 8, 2026
0

The upcoming quarterly report from Outdoor Holding Company, formerly known as Ammo, represents a critical milestone. Investors...

Berry Petroleum Stock

California Resources Navigates Post-Merger Integration and Regulatory Landscape

February 8, 2026
KemPharm Stock

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

February 8, 2026
Oak Valley Stock

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

February 8, 2026
SuRo Capital Stock

SuRo Capital Sharpens Focus on AI Infrastructure Investments

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Outdoor Holding Company’s Pivot Faces Crucial Quarterly Test
  • California Resources Navigates Post-Merger Integration and Regulatory Landscape
  • Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com